Lawrence Yanxi Lu

Lawrence Yanxi Lu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2023 in Chest
Verified
Journal Article
Closed access
LLLawrence Yanxi Lu
Lawrence Yanxi Lu
HLHui Min Lee
Hui Min Lee
ABAndrew Burke
Andrew Burke
GBGianluigi Li Bassi
Gianluigi Li Bassi
ATAntoni Torres
Antoni Torres
JFJonathon P. Fanning
Jonathon P. Fanning

28 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LLLawrence Yanxi Lu
Lawrence Yanxi Lu
JEJacques Eastment
Jacques Eastment
YSYogeesan Sivakumaran
Yogeesan Sivakumaran
Median arcuate ligament syndrome (MALS) is an uncommon condition characterized by the compression of the celiac trunk by the median arcuate ligament. Due to the anatomical proximity to the foregut, MALS has significant implications in hepato-pancreato-biliary (HPB) surgery. It can pose complications in pancreatoduodenectomy and orthotopic liver transplantation, where the collateral arterial supply from the superior mesenteric artery is often disrupted. The estimated prevalence of MALS in HPB surgery is approximately 10%. Overall, there is consensus for a cautious approach to MALS when embarking on complex foregut surgery, with a low threshold for intraoperative median arcuate ligament release or hepatic artery reconstruction. The role of endovascular intervention in the management of MALS prior to HPB surgery continues to evolve, but more evidence is required to establish its efficacy. Recognizing the existing literature gap concerning optimal management in this population, we describe our tertiary center experience as a clinical algorithm to facilitate decision-making. Research question: What is the significance and management of median arcuate ligament syndrome in patients undergoing hepato-pancreato-biliary surgery?

20 July 2023 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
NONchafatso Gikenyi Obonyo
Nchafatso Gikenyi Obonyo
LLLawrence Yanxi Lu
Lawrence Yanxi Lu
NWNicole White
Nicole White
DSDeclan P. Sela
Declan P. Sela
RRReema H. Rachakonda
Reema H. Rachakonda
John Francis FraserJohn Francis Fraser
John Francis Fraser
Objective: To investigate associations between transfusion of blood products close to the end of shelf‐life and clinical outcomes in obstetric inpatients.Methods: Mortality and morbidity were compared in patients transfused exclusively with red blood cells (RBC) stored for less than 21 days (fresh) versus RBC stored for 35 days or longer (old), and platelets (PLT) stored for 3 days or fewer (fresh) versus 4 days or longer (old) in Queensland, Australia from 2007 to 2013. Multivariable models were used to examine associations between these groups of blood products and clinical end points.Results: There were 3371 patients who received RBC and 280 patients who received PLT of the eligible storage durations. Patients transfused with old RBC received fewer transfusions (2.7 ± 1.8 vs. 2.3 ± 1.0 units; P < 0.001). However, a higher rate of single‐unit transfusions was also seen in those patients who exclusively received old RBC (252 [9.3%] vs. 92 [13.7%]; P = 0.003). Comparison of fresh vs. old blood products revealed no differences in the quantities of transfused RBC (9.5 ± 5.9 vs. 9.1 ± 5.2 units; P = 0.680) or PLT (1.5 ± 0.8 vs. 1.4 ± 1.1 units; P = 0.301) as well as the length of hospital stay for RBC (3 [2–5] vs. 3 [2–5] days; P = 0.124) or PLT (5 [4–8] vs. 6 [4–9] days; P = 0.120).Conclusion: Transfusing exclusively older RBC or PLT was not associated with increased morbidity or mortality.

27 June 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
NMN. McCormick
N. McCormick
LLLawrence Yanxi Lu
Lawrence Yanxi Lu
CYC. Yokose
C. Yokose
AJA. Joshi
A. Joshi
YZY. Zhang
Y. Zhang
HCH. Choi
H. Choi
Background Serum urate (SU) is a necessary causal factor for development of gout, while chronic kidney disease (CKD) is associated with increased inflammatory biomarkers, cytokines, and reduced AMPK activity levels. Furthermore, CKD has been found to be associated with an increased risk of incident gout, even beyond (i.e., independent of) SU levels. As such, the impact of SU may be enhanced by presence of CKD, but this hypothesis has not been evaluated. Objectives To prospectively examine whether CKD modifies the relation between SU levels and risk of incident gout. Methods We conducted a prospective cohort analysis of UK Biobank participants with urate and creatinine levels available from baseline blood samples (2006-2010), and no prior diagnosis of gout or urate lowering therapy use. CKD Stage ≥ 3 status (eGFR <60 mL/min) was determined from latest CKD-Epi equations (NEJM 2021; JASN 2021).1,2 Incident cases of gout were ascertained from linked hospitalisation, primary care, and death records. Participants were followed from baseline up to 10 years or until gout diagnosis, death, or end of study period (Dec 31/19). We calculated 10-year cumulative incidence of gout according to baseline SU category and CKD status and evaluated their individual and joint impact on gout risk using multivariable Cox proportional hazards models. We further assessed for additive and multiplicative interactions3 between levels of SU and inverted eGFR, on a standardized continuous scale per SD. Results We included 458,244 individuals (45% male, mean age 56.5 years), of whom 6,559 had CKD at baseline, and documented 5,847 cases of incident gout over 4,442,866 person-years. 10-year cumulative incidence of gout ranged from 0.2% (baseline SU < 5 mg/dL) to 33% (baseline SU ≥ 10 mg/dL), and in each category incidence was higher for those with CKD than without (Table 1; Figure 1-left), Multivariable hazard ratio (HR) for the joint effect of CKD and highest SU level (≥ 10 mg/dL), compared to non-CKD and lowest SU (<5mg/dL), was 242 (95% CI: 189 to 309) (Figure 1-right). Cumulative incidence and hazard ratio (HR) of incident gout according to baseline serum urate levels and CKD status There was a significant additive interaction between continuous SU and eGFR (relative excess risk due to interaction=0.16 [0.09 to 0.24], p < 0.001), with HRs of 3.7 (3.6 to 3.8) per SD increase of SU, 1.2 (1.2 to 1.3) per SD increase of inverted eGFR, and 4.1 (3.9 to 4.2) for their joint effect. Their multiplicative interaction was also significant (p < 0.001). Conclusion These large prospective cohort data suggest CKD presence enhances the effect of elevated SU levels on risk of incident gout. They support roles of CKD-associated factors beyond SU in developing gout, such as reduced AMPK activity levels and altered inflammatory factors in CKD, which warrant further investigation. References [1]PMID 34554658 [2]PMID 34556489 [3]ARD (2021) PMID 34857519 Disclosure of Interests Natalie McCormick: None declared, Leo Lu: None declared, Chio Yokose: None declared, Amit Joshi: None declared, Yuqing Zhang: None declared, Hyon Choi Consultant of: Ironwood, Selecta, Horizon, Takeda, Kowa, and Vaxart., Grant/research support from: Ironwood and Horizon

20 August 2025 in Journal of Vascular Research
Verified
Journal Article
Open access
NONchafatso Gikenyi Obonyo
Nchafatso Gikenyi Obonyo
LLLawrence Yanxi Lu
Lawrence Yanxi Lu
ZNZohaib Nadeem
Zohaib Nadeem
ZHZahra Hosseinzadeh
Zahra Hosseinzadeh
RRReema Rachakonda
Reema Rachakonda
JFJohn Fraser
John Fraser
Introduction: We investigated the effects of transfusing blood products close to the expiration date (i.e., ≥35 days packed red blood cells [PRBCs] and >3 days platelets [PLTs]) on vascular patients. Methods: We retrospectively examined all PRBC and PLT transfusions in patients who underwent vascular procedures without cardiopulmonary bypass in Queensland from 2007 to 2013. Mortality, length of stay (LOS), and blood product quantities were compared in patients transfused exclusively with PRBCs 3 days. Results: No significant mortality difference was found between patients transfused fresh vs. old PRBCs (26/493 [5.3%] vs. 6/152 [3.9%]; OR 0.75; 95% CI: 0.3–1.9). Patients transfused fresh PRBCs experienced a longer LOS (11 days [IQR: 7–20] vs. 10 days [IQR: 7–15]; 95% CI: −4.8 to −0.24) and more PRBC units (3.9 ± 4.5 units vs. 2.1 ± 1.3 units; 95% CI: −2.3 to −0.9). Among patients transfused PLTs, there were no significant differences in mortality (24/124 [19.4%] vs. 14/78 [17.9%]; OR 1.0; 95% CI: 0.5–2.3) between patients transfused fresh vs. old PLTs. Conclusion: Within the limitations of the retrospective study design, transfusion of older PRBCs or PLTs was associated with fewer transfused units, shorter hospital stays, but no difference in mortality.